Cargando…

The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China

OBJECTIVE: To evaluate the diagnostic value of gastrin-17 (G-17) and pepsinogen (PG) in gastric cancer (GC) screening in China, especially eastern China, and to determine the best diagnostic combination and threshold (cutoff values) to screen out patients who need gastroscopy. METHODS: The serum con...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hongzhang, Xiong, Kangwei, Wu, Xiangyu, Cheng, Sile, Lou, Qifeng, Jin, Hangbin, Zhang, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055402/
https://www.ncbi.nlm.nih.gov/pubmed/33936196
http://dx.doi.org/10.1155/2021/6894248
_version_ 1783680441457311744
author Shen, Hongzhang
Xiong, Kangwei
Wu, Xiangyu
Cheng, Sile
Lou, Qifeng
Jin, Hangbin
Zhang, Xiaofeng
author_facet Shen, Hongzhang
Xiong, Kangwei
Wu, Xiangyu
Cheng, Sile
Lou, Qifeng
Jin, Hangbin
Zhang, Xiaofeng
author_sort Shen, Hongzhang
collection PubMed
description OBJECTIVE: To evaluate the diagnostic value of gastrin-17 (G-17) and pepsinogen (PG) in gastric cancer (GC) screening in China, especially eastern China, and to determine the best diagnostic combination and threshold (cutoff values) to screen out patients who need gastroscopy. METHODS: The serum concentrations of G-17 and pepsinogen I and II (PGI and PGII) in 834 patients were analyzed, and the PGI/PGII ratio (PGR) was calculated. According to pathological results, patients can be divided into chronic nonatrophic gastritis (NAG)/chronic atrophic gastritis (CAG)/intraepithelial neoplasia (IN)/GC groups. The differences in G-17, PG, and PGR in each group were analyzed, and their values in GC diagnosis were evaluated separately and in combination. RESULTS: There were differences in serum G-17, PGII, and PGR among the four groups (NAG/CAG/IN/GC) (P ≤ 0.001). In total, 54 GC cases were diagnosed, of which 50% were early GC. There was no significant difference in the PGI levels among the four groups (P = 0.377). NAG and CAG composed the chronic gastritis (CG) group. The G-17 and PGII levels in the IN and GC groups were higher than those in the CG group (both P ≤ oth C), while the PGR levels were lower (P ≤ lower). When distinguishing NAG from CAG, the best cutoff value for G-17 was 9.25 pmol/L, PGII was 7.06 μg/L, and PGR was 12.07. When distinguishing CG from IN, the best cutoff value for G-17 was 3.86 pmol/L, PGII was 11.92 μg/L, and PGR was 8.26. When distinguishing CG from GC, the best cutoff value for G-17 was 3.89 pmol/L, PGII was 9.16 μg/L, and PGR was 14.14. The sensitivity, specificity, accuracy, and positive and negative predictive values of G-17/PGII/PGR for GC diagnosis were 83.3%/70.4%/79.6%, 51.8%/56.3%/47.8%, 53.8%/57.2%/49.9%, 10.7%/10.9%/9.6%, and 97.8%/96.5%/97.1%, respectively. The sensitivity, specificity, accuracy, and positive predictive and negative predictive values of PGII/G-17 vs. PGR/G-17 vs. PGR/PGII in the diagnosis of GC were 63.0% vs. 70.4% vs. 64.8%, 70.5% vs. 70.1% vs. 60.4%, 70.0% vs. 70.1% vs. 60.7%, 12.9% vs. 14.0% vs. 10.2%, and 96.5% vs. 97.2% vs. 96.1%, respectively. CONCLUSION: The PGII and G-17 levels in patients with gastric IN and GC were significantly increased, while the serum PGR level was significantly decreased. Serological detection is effective for screening GC. The combination of different markers can improve the diagnostic efficiency. The highest diagnostic accuracy was G-17 combined with PGR, and the best cutoff values were G − 17 > 3.89 pmol/L and PGR < 14.14.
format Online
Article
Text
id pubmed-8055402
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-80554022021-04-29 The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China Shen, Hongzhang Xiong, Kangwei Wu, Xiangyu Cheng, Sile Lou, Qifeng Jin, Hangbin Zhang, Xiaofeng Gastroenterol Res Pract Research Article OBJECTIVE: To evaluate the diagnostic value of gastrin-17 (G-17) and pepsinogen (PG) in gastric cancer (GC) screening in China, especially eastern China, and to determine the best diagnostic combination and threshold (cutoff values) to screen out patients who need gastroscopy. METHODS: The serum concentrations of G-17 and pepsinogen I and II (PGI and PGII) in 834 patients were analyzed, and the PGI/PGII ratio (PGR) was calculated. According to pathological results, patients can be divided into chronic nonatrophic gastritis (NAG)/chronic atrophic gastritis (CAG)/intraepithelial neoplasia (IN)/GC groups. The differences in G-17, PG, and PGR in each group were analyzed, and their values in GC diagnosis were evaluated separately and in combination. RESULTS: There were differences in serum G-17, PGII, and PGR among the four groups (NAG/CAG/IN/GC) (P ≤ 0.001). In total, 54 GC cases were diagnosed, of which 50% were early GC. There was no significant difference in the PGI levels among the four groups (P = 0.377). NAG and CAG composed the chronic gastritis (CG) group. The G-17 and PGII levels in the IN and GC groups were higher than those in the CG group (both P ≤ oth C), while the PGR levels were lower (P ≤ lower). When distinguishing NAG from CAG, the best cutoff value for G-17 was 9.25 pmol/L, PGII was 7.06 μg/L, and PGR was 12.07. When distinguishing CG from IN, the best cutoff value for G-17 was 3.86 pmol/L, PGII was 11.92 μg/L, and PGR was 8.26. When distinguishing CG from GC, the best cutoff value for G-17 was 3.89 pmol/L, PGII was 9.16 μg/L, and PGR was 14.14. The sensitivity, specificity, accuracy, and positive and negative predictive values of G-17/PGII/PGR for GC diagnosis were 83.3%/70.4%/79.6%, 51.8%/56.3%/47.8%, 53.8%/57.2%/49.9%, 10.7%/10.9%/9.6%, and 97.8%/96.5%/97.1%, respectively. The sensitivity, specificity, accuracy, and positive predictive and negative predictive values of PGII/G-17 vs. PGR/G-17 vs. PGR/PGII in the diagnosis of GC were 63.0% vs. 70.4% vs. 64.8%, 70.5% vs. 70.1% vs. 60.4%, 70.0% vs. 70.1% vs. 60.7%, 12.9% vs. 14.0% vs. 10.2%, and 96.5% vs. 97.2% vs. 96.1%, respectively. CONCLUSION: The PGII and G-17 levels in patients with gastric IN and GC were significantly increased, while the serum PGR level was significantly decreased. Serological detection is effective for screening GC. The combination of different markers can improve the diagnostic efficiency. The highest diagnostic accuracy was G-17 combined with PGR, and the best cutoff values were G − 17 > 3.89 pmol/L and PGR < 14.14. Hindawi 2021-04-12 /pmc/articles/PMC8055402/ /pubmed/33936196 http://dx.doi.org/10.1155/2021/6894248 Text en Copyright © 2021 Hongzhang Shen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shen, Hongzhang
Xiong, Kangwei
Wu, Xiangyu
Cheng, Sile
Lou, Qifeng
Jin, Hangbin
Zhang, Xiaofeng
The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China
title The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China
title_full The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China
title_fullStr The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China
title_full_unstemmed The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China
title_short The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China
title_sort diagnostic value of serum gastrin-17 and pepsinogen for gastric cancer screening in eastern china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055402/
https://www.ncbi.nlm.nih.gov/pubmed/33936196
http://dx.doi.org/10.1155/2021/6894248
work_keys_str_mv AT shenhongzhang thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT xiongkangwei thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT wuxiangyu thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT chengsile thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT louqifeng thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT jinhangbin thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT zhangxiaofeng thediagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT shenhongzhang diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT xiongkangwei diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT wuxiangyu diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT chengsile diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT louqifeng diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT jinhangbin diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina
AT zhangxiaofeng diagnosticvalueofserumgastrin17andpepsinogenforgastriccancerscreeningineasternchina